Thienodibenzoazulene compounds as tumor necrosis factor inhibitors

Dibenzoazulene derivatives, their pharmacologically acceptable salts and solvates represented by formula I

• 4
• characterized in that
• X can represent CH2 or a heteroatom such as O, S, S(═O), S(═O)2 or NR13, wherein R13 means hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, arylcarbonyl, C1-6 alkylsulfonyl or arylsulfonyl and R1, R2, R3, R4, R5, R6, R7, R8, R9 independently from each other represent substituents, which can be hydrogen, halogens (fluorine, chlorine or bromine);
• or C1-C7 alkyls, alkenyls, aryls or heteroaryls;
• or can represent different groups:
• halomethyl, hydroxy, C1-C7 alkoxy or aryloxy, C1-C7 alkylthio or arylthio, C1-C7 alkylsulfonyl, ciano, amino, mono- and di-C1-C7 substituted amines, derivatives of carboxylic group (C1-C7 carboxylic acids and their anhydrides, C1-C7 unsubstituted, mono-, di-substituted amides, C1-C7 alkyl or aryl esters), C1-C7 derivatives of carbonyl group (C1-C7 alkyl or aryl carbonyls), and R10 can represent substituents such as:
• C2-C15 alkyls, C2-C15 alkenyls, C2-C15 alkinyls, aryls or heteroaryls, C1-C15 haloalkyls, C1-C15 hydroxyalkyls, C1-C15 alkyloxy, C1-C15 alkylthio, C3-C15 alkylcarbonyls, C2-C15 alkylcarboxylic acid, C2-C15 alkylsters, C1-C15 alkylsulfonyls, C1-C15 alkylarylsulfonyls, arysulfonyls and C1-C15 alkylamines represented by the general formula
• —(CH2)n—A
• wherein
• n means l-15, and
• one or more methylene groups that can be substituted with an oxygen or sulfur atom, and
• A represents a five- or six-membered, saturated or unsaturated ring with one, two or three heteroatoms, or
• 5
• wherein R11 and R12 independently from each other represent hydrogen, C1-C7 alkyl, C alkenyl, alkinyl, aryl or heteroaryl, or a heterocycle with 1-3 beteroatoms.